|
|
|
| An epidemiological investigation on vaccine-hypervariable poliovirus in a case with acute flaccid paralysis in Zhejiang Province |
| TANG Xuewen1, GONG Liming2, ZHOU Yang1, YAN Rui1, DENG Xuan1, ZHU Yao1, HE Hanqing1
|
1. Department of Immunization Program, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang 310051, China;
2. Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang 310051, China |
|
|
|
|
Abstract Vaccine-hypervariable poliovirus type Ⅲ was detected in an acute flaccid paralysis infant at age of 6 months in Zhejiang Province in June, 2021, and the isolated and incubated virus had six nucleotide variations in the VP1 region as compared to the poliovirus Sabin vaccine strain. The infant had a history of three-dose poliovirus vaccination, and grade 2 muscle strength of the left upper limb upon onset. He was clinically diagnosed with cellulitis of the left shoulder, and recovered to normal following treatment. No abnormality was detected in the nervous system, and the infant was cured and discharged from hospital. No vaccine-hypervariable poliovirus was detected in subsequent infant' clinical samples or in close contacts, and no similar cases were identified during the active case detection by county/district medical institutions and among community populations. Since the infant did not present poliomyelitis-related clinical symptoms caused by vaccine-hypervariable poliovirus, poliomyelitis was excluded. The vaccine-hypervariable poliovirus was not spread because of timely identification and effective responses, suggesting the urgent need to maintain the sensitivity of the acute flaccid paralysis surveillance system and improve the coverage of poliovirus vaccination, so as to inhibit the transmission of poliovirus.
|
|
Received: 30 August 2022
Revised: 24 October 2022
Published: 11 January 2023
|
|
|
|
|
|
[1] BIGOUETTE J P,WILKINSON A L,TALLIS G,et al.Progress toward polio eradication-worldwide,January 2019-June 2021[J].MMWR,2021,70(34):1129-1135.
[2] PATEL M,COCHI S.Addressing the challenges and opportunities of the polio endgame:lessons for the future[J/OL].J Infect Dis,2017[2022-10-24].https://doi.org/10.1093/infdis/jix117.
[3] SULTAN M A.Emerging challenges to realizing global polio eradication and their solutions[J].East Mediterr Health J,2022,28(7):515-520.
[4] 中华人民共和国国家卫生和计划生育委员会.脊髓灰质炎诊断:WS/T 294—2016[S].2016.
[5] KEW O,PALLANSCH M.Breaking the last chains of poliovirus transmission:progress and challenges in global polio eradication[J].Annu Rev Virol,2018,5(1):427-451.
[6] GARON J,SEIB K,ORENSTEIN W A,et al.Polio endgame:the global switch from tOPV to bOPV[J].Vaccines,2016,15(6):693-708.
[7] 祝双利,李晓嫘,朱晖,等.中国2015年脊髓灰质炎实验室网络的运转与评价[J].中国疫苗和免疫,2017,23(2):127-133.
[8] 唐学雯,周洋,邓璇,等.浙江省实施脊髓灰质炎疫苗免疫新策略的卫生经济学评价[J].预防医学,2017,29(12):1199-1202.
[9] 郭世成,胡志勇,刘莉红,等.江西省首例免疫缺陷疫苗衍生脊灰病毒病例的调查[J].现代预防医学,2016,43(5):922-924,930.
[10] YAO N,LIU Y,XU J W,et al.Detection of a highly divergent type 3 vaccine-derived poliovirus in a child with a severe primary
immunodeficiency disorder-Chongqing,China,2022[J].MMWR,2022,71(36):1148-1150.
[11] 龚震宇,龚训良.全球消除脊髓灰质炎进展[J].预防医学,2022,34(8):861-862.
[12] SHARIF S,ABBASI B H,KHURSHID A,et al.Evolution and circulation of type-2 vaccine-derived polioviruses in Nad Ali district of Southern Afghanistan during June2009-February 2011[J/OL].PLoS One,2014,9(2)[2022-10-24].https://doi.org/10.1371/journal.pone.0088442.
[13] HSU C H,HARVEY B,MOHAMED A,et al.Assessment of in-country capacity to maintain communicable disease surveillance and response services after polio eradication-Somalia[J].Vaccine,2020,38(5):1220-1224.
[14] 刘宇,方刚,杜飞,等.四川省Ⅱ型疫苗高变异脊髓灰质炎病毒/疫苗衍生脊髓灰质炎病毒循环事件的现场流行病学调查与分析[J].中国疫苗和免疫,2013,19(5):407-412.
[15] GOODMAN B.New York adult diagnosed with polio,first US case in nearly a decade[EB/OL].(2022-07-22)[2022-10-24].https://edition.cnn.com/2022/07/21/health/new-york-polio/index.html. |
|
|
|
